Clinical approach in treatment of resistant hypertension

References

• CalhounDAJonesDTextorSResistant hypertension: diagnosis, evaluation, and treatment: a scientific statementfrom the American Heart Association Professional Education Committee of the Council for High Blood Pressure ResearchCirculation200811725e510e52618574054
   PubMed Web of Science ®Google Scholar
• EpsteinMResistant hypertension: prevalence and evolving conceptsJ Clin Hypertens (Greenwich)200791 Suppl 12617215648
   PubMedGoogle Scholar
• MoserMSetaroJFResistant or difficult-to-control hypertensionN Engl J Med2006355438539216870917
   PubMed Web of Science ®Google Scholar
• CuspidiCMaccaGSampeiriLHigh prevalence of cardiac and extracardiac target organ damage in refractory hypertensionJ Hypertens200119112063207011677373
   PubMed Web of Science ®Google Scholar
• PierdomenicoSDLapennaDBucciACardiovascular outcome in treated hypertensive patients with responder, masked, false resistant, and true resistant hypertensionAm J Hypertens200518111422142816280275
   PubMed Web of Science ®Google Scholar
• ErdineSArat-OzkanAResistant HypertensionBlood Press2003125–634734814763668
   PubMedGoogle Scholar
• CalhounDANishikazaMKZamanAThakkarRBWeissmannPHyperaldosteronism among black and white subjects with resistant hypertensionHypertension200240689289612468575
   PubMed Web of Science ®Google Scholar
• GaddamKKNishizakaMKPratt-UbunamaMCharacterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansionArch Intern Med2008168111159116418541823
   PubMedGoogle Scholar
• PimentaEGaddamKKOparilSMechanisms and treatment of resistant hypertensionJ Clin Hypertens (Greenwich)200810323924418326968
   PubMed Web of Science ®Google Scholar
• CalhounDALow-dose aldosterone blockade as a new treatment paradigm for controlling resistant hypertensionJ Clin Hypertens (Greenwich)200791 Suppl 1192417215651
   PubMedGoogle Scholar
• BrownMABuddleMLMartinAIs resistant hypertension really resistant?Am J Hypertens200114121263126911775136
   PubMed Web of Science ®Google Scholar
• ParkJCampeseVClinical characteristics of resistant hypertension: the importance of compliance and the role of diagnostic evaluation in delineating pathogenesisJ Clin Hypertens (Greenwich)200791 Suppl 171217215649
   PubMedGoogle Scholar
• TrewetCLBErnstMEResistant hypertension: identifying causes and optimizing treatment recommendationsSouthern Med J2008101216617318364619
   PubMed Web of Science ®Google Scholar
• VidtDGPathogenesis and treatment of resistant hypertensionMinerva Med200394420121414605586
   PubMedGoogle Scholar
• PickeringTGArterial stiffness as a cause of resistant hypertension?J Clin Hypertens (Greenwich)20079539039517485975
   PubMedGoogle Scholar
• MuxfeldtESBlochKVda Rocha NogueiraASallesGHTrue resistant hypertension: is it possible to be recognized in the office?Am J Hypertens200518121534154016364821
   PubMed Web of Science ®Google Scholar
• HallJEThe kidney, hypertension, and obesityHypertension200341part 262563312623970
   PubMed Web of Science ®Google Scholar
• KaplanNMResistant hypertensionJ Hypertens20052381441144416003165
   PubMed Web of Science ®Google Scholar
• HallWDResistant hypertension, secondary hypertension, and hypertensive crisesCardiol Clin20022 20:28128912119801
   PubMedGoogle Scholar
• Cadaval GoncalvesSMartinezDGusMObstructive sleep apnea and resistant hypertension: a case-control studyChest200713261858186218079220
   PubMed Web of Science ®Google Scholar
• Pratt-UbunamaMNNishizakaMKBoedefeldRLCofieldSSHardingSMCalhounDAPlasma aldosterone is related to severity of obstructive sleep apnea in subjects with resistant hypertensionChest2007131245345917296647
   PubMed Web of Science ®Google Scholar
• CalhounDANishizakaMKZamanMAHardingSMAldosterone excretion among subjects with resistant hypertension and symptoms of sleep apneaChest2004125111211714718429
   PubMed Web of Science ®Google Scholar
• DoumaSPetidisKDoumasMPrevalence of primary aldoste-ronism in resistant hypertension: a retrospective observational studyLancet200837196281921192618539224
   PubMed Web of Science ®Google Scholar
• EpsteinMCalhounDAThe role of aldosterone in resistant hypertension: implications for pathogenesis and therapyCurr Hypertens Rep2007929810517442219
   PubMed Web of Science ®Google Scholar
• DuprezDAAldosterone and the vasculature: mechanisms mediating resistant hypertensionJ Clin Hypertens (Greenwich)200791 Suppl 1131817215650
   PubMedGoogle Scholar
• GrimCEEvolution of diagnostic criteria for primary aldosteronism: why is it more common in “drug-resistant” hypertension today?Curr Hypertens Rep20046648549215527695
   PubMed Web of Science ®Google Scholar
• SartoriMCaloLAMascagnaVAldosterone and refractory hypertension: a prospective cohort studyAm J Hypertens200619437337916580572
   PubMed Web of Science ®Google Scholar
• PimentaECalhounDAResistant hypertension and aldosteronismCurr Hypertens Rep20079535335918177580
   PubMed Web of Science ®Google Scholar
• PimentaECalhounDAOparilSMechanisms and treatment of resistant hypertensionArq Bras Cardiol2007886604613
   Web of Science ®Google Scholar
• CampeseVMMitraNSandeeDHypertension in renal parenchymal disease: why is it so resistant to treatment?Kidney Int200669696797316528245
   PubMed Web of Science ®Google Scholar
• BurnierMSantschiVFavratBBrunnerHRMonitoring compliance in resistant hypertension: an important step in patient managementJ Hypertens200321Suppl 2S37S42
   Web of Science ®Google Scholar
• PickeringTGHallJEAppelLJRecommendations for blood pressure management in humans and experimental animals: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure ResearchCirculation2005111569771615699287
   PubMed Web of Science ®Google Scholar
• HickmanPELeongMChangJWilsonSRMcWhinneyBPlasma free metanephrines are superior to urine and plasma catecholamines and urine catecholamine metabolites for the investigation of phaeochromocytomaPathology200941217317719152190
   PubMed Web of Science ®Google Scholar
• CuspidiCMeaniSValerioCFusiVSalaCZanchettiALeft ventricular hypertrophy and cardiovascular risk stratification: impact and cost-effectiveness of echocardiography in recently diagnosed essential hypertensivesJ Hypertens20062481671167716877972
   PubMed Web of Science ®Google Scholar
• KawashimaAFrancisIRBaumgartenDAfor the Expert Panel on Urologic ImagingRenovascular hypertension [online publication]Reston (VA)American College of Radiology (ACR)20079
   Google Scholar
• ChobanianAVBakrisGLBlackHRThe Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 reportJAMA2003289192560257212748199
   PubMed Web of Science ®Google Scholar
• CalhounDAResistant or difficult-to-control hypertensionJ Clin Hypertens (Greenwich)20068318118616522995
   PubMedGoogle Scholar
• HermidaRCAyalaDECalvoCEffects of time of day of treatment on ambulatory blood pressure pattern of patients with resistant hypertensionHypertension20054641053105916087787
   PubMed Web of Science ®Google Scholar
• HermidaRCAyalaDEFernandezJRCalvoCChronotherapy improves blood pressure control and reverts the nondipper pattern in patients with resistant hypertensionHypertension2008511697617968001
   PubMed Web of Science ®Google Scholar
• DolanEStantonAThijsLSuperiority of ambulatory over clinic blood pressure measurement in predicting mortality: the Dublin outcome studyHypertension200546115616115939805
   PubMed Web of Science ®Google Scholar
• KikuyaMOhkuboTAsayamaKAmbulatory blood pressure and 10-year risk of cardiovascular and noncardiovascular mortality: the Ohasama studyHypertension200545224024515596571
   PubMed Web of Science ®Google Scholar
• StaessenJAThijsLFagardRfor the Systolic Hypertension in Europe Trial InvestigatorsPredicting cardiovascular risk using conventional vs. ambulatory blood pressure in older patients with systolic hypertensionJAMA1999282653954610450715
   PubMed Web of Science ®Google Scholar
• BrotmanDJDavidsonMBBoumitriMVidtDGImpaired diurnal blood pressure variation and all-cause mortalityAm J Hypertens2008211929718091750
   PubMed Web of Science ®Google Scholar
• De SouzaWAYugar-ToledoJCBergsten-MendesGSabhaMMorenoHEffect of pharmaceutical care on blood pressure control and health-related quality of life in patients with resistant hypertensionAm J Health-Syst Pharm200764181955196117823108
   PubMed Web of Science ®Google Scholar
• TalerSJShould chlorthalidone be the diuretic of choice for antihypertensive therapy?Curr Hypertens Rep200810429329718625158
   PubMed Web of Science ®Google Scholar
• HandlerJMaximizing diuretic therapy in resistant hypertensionJ Clin Hypertens (Greenwich)200791080280617917510
   PubMedGoogle Scholar
• ErnstMECarterBLGoerdtCJComparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressureHypertension200647335235816432050
   PubMed Web of Science ®Google Scholar
• CarterBLErnstMECohenJDHydrochlorothiazide versus chlorthalidone: evidence supporting their interchangeabilityHypertension20044314914638621
   PubMed Web of Science ®Google Scholar
• MoserMCushmanWHandlerJResistant or difficult-to-treat hypertensionJ Clin Hypertens (Greenwich)20068643444016760683
   PubMedGoogle Scholar
• SarafidisPABakrisGLResistant hypertension: an overview of evaluation and treatmentJ Am Coll Cardiol200852221749175719022154
   PubMed Web of Science ®Google Scholar
• ChapmanNDobsonJWilsonSfor Anglo-Scandinavian Cardiac Outcomes Trial InvestigatorsEffect of spironolactone on blood pressure in subjects with resistant hypertensionHypertension200749483984517309946
   PubMed Web of Science ®Google Scholar
• LaneDAShahSBeeversDGLow-dose spironolactone in the management of resistant hypertension: a surveillance studyJ Hypertens200725489189417351384
   PubMed Web of Science ®Google Scholar
• MahmudAMahgoubMHallMFeelyJDoes aldosterone-to-renin ratio predict the antihypertensive effect of the aldosterone antagonist spironolactone?Am J Hypertens20051812 Pt 11631163516364838
   PubMed Web of Science ®Google Scholar
• NishizakaMKZamanMACalhounDAEfficacy of low-dose spironolactone in subjects with resistant hypertensionAm J Hypertens20031611 Pt 192593014573330
   PubMed Web of Science ®Google Scholar
• OuzanJPeraultCLincoffAMCarreEMertesMThe role of spironolactone in the treatment of patients with refractory hypertensionAm J Hypertens2002154 Pt 133333911991219
   PubMed Web of Science ®Google Scholar
• NishkzakaMKCalhoundDAThe role of aldosterone antagonists in the management of resistant hypertensionCurr Hypertens Rep20057534334716157075
   PubMed Web of Science ®Google Scholar
• CalhounDAUse of aldosterone antagonists in resistant hypertensionProg Cardiovasc Dis200648638739616714158
   PubMed Web of Science ®Google Scholar
• GaddamKKPratt-UbunamaMNCalhounDAAldosterone antagonists: effective add-on therapy for the treatment of resistant hypertensionExpert Rev Cardiovasc Ther20064335335916716096
   PubMedGoogle Scholar
• EideIKTorjesenPADrolsumABabovicALilledahlNPLow-renin status in therapy-resistant hypertension: a clue to efficient treatmentJ Hypertens200422112217222615480108
   PubMed Web of Science ®Google Scholar
• LaneDABeeversDGAmiloride 10 mg is less effective than spironolactone 25 mg in patients with hypertension resistant to a multidrug regimen including an angiotensin-blocking agentJ Hypertens200725122515251617984678
   PubMed Web of Science ®Google Scholar
• DoraJMKramerCKCananiLHStandards of Medical Care in Diabetes – 2008: response to Hirsch, Inzucchi, and KirkmanDiabetes Care2008315e44 author reply e5.18445724
   PubMedGoogle Scholar
• StergiouGSMakrisTPapavasiliouMEfstathiouSManolisAComparison of antihypertensive effects of an angiotensin-converting enzyme inhibitor, a calcium antagonist and a diuretic in patients with hypertension not controlled by angiotensin receptor blocker monotherapyJ Hypertens200523488388915775795
   PubMed Web of Science ®Google Scholar
• YusufSTeoKKPogueJTelmisartan, ramipril, or both in patients at high risk for vascular eventsThe New England journal of medicine2008358151547155918378520
   PubMed Web of Science ®Google Scholar
• PfefferMAMcMurrayJJVelazquezEJValsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or bothN Engl J Med2003349201893190614610160
   PubMed Web of Science ®Google Scholar
• AriciMErdemYDual blockade of the renin-angiotensin system for cardiorenal protection: an updateAm J Kidney Dis200953233234519166800
   PubMed Web of Science ®Google Scholar
• BakrisGLWeirMRAngiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern?Arch Intern Med2000160568569310724055
   PubMed Web of Science ®Google Scholar
• MuntwylerJFollathFCalcium channel blockers in treatment of hypertensionProg Cardiovasc Dis200144320721611727278
   PubMed Web of Science ®Google Scholar
• SawickiPTSiebenhoferABetablocker treatment in diabetes mellitusJ Intern Med20012501111711454137
   PubMed Web of Science ®Google Scholar
• SoRelleRNational Heart, Lung, and Blood Institute halts part of antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)Circulation200010112E902510736305
   PubMedGoogle Scholar
• TalerSJTreatment of resistant hypertensionCurr Hypertens Rep20057532332916157072
   PubMed Web of Science ®Google Scholar
• MannSJCombined alpha/beta-blockade: an underused approach to the treatment of resistant hypertensionJ Clin Hypertens200799663664
   Google Scholar
• SicaDAMinoxidil: an underused vasodilator for resistant or severe hypertensionJ Clin Hypertens (Greenwich)20046528328715133413
   PubMedGoogle Scholar
• JacksonKC2ndShengXNelsonREKeskinaslanABrixnerDIAdherence with multiple-combination antihypertensive pharmacotherapies in a US managed care databaseClinical therapeutics20083081558156318803997
   PubMed Web of Science ®Google Scholar
• ChrysantSGUsing fixed-dose combination therapies to achieve blood pressure goalsClin Drug Investig20082811713734
   PubMed Web of Science ®Google Scholar
• BlackHRBakrisGLWeberMAEfficacy and safety of darusentan in patients with resistant hypertension: results from a randomized, double-blind, placebo-controlled dose-ranging studyJ Clin Hypertens (Greenwich)200791076076917917503
   PubMedGoogle Scholar
• EpsteinBJEfficacy and safety of darusentan: a novel endothelin receptor antagonistAnn Pharmacother20084271060106918523233
   PubMed Web of Science ®Google Scholar
• BakrisGCalhounDEgaBfor orlistat and resistant hypertension investigatorsOrlistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertensionJ Hypertens200220112257226712409965
   PubMed Web of Science ®Google Scholar
• SloandJAIlligKABisognanoJDImproved control of resistant hypertension with device-mediated electrical carotid sinus baroreflex stimulationJ Clin Hypertens (Greenwich)20079971671917786075
   PubMedGoogle Scholar
• GyamlaniGGeraciSASecondary hypertension due to drugs and toxinsSouthern Med J2007100769269917639749
   PubMed Web of Science ®Google Scholar
• PadillaMCAArmas-HernandezMJHernandezRHIsrailiZHValascoMUpdate of diuretics in the treatment of hypertensionAm J Ther200714215416017414583
   PubMedGoogle Scholar